Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.

Abstract: An anode for a lithium secondary battery includes an anode current collector, and an anode active material layer formed on at least one surface of the anode current collector. The anode active material layer includes a carbon-based active material, a first silicon-based active material including a carbon-silicon composite active material, and a second silicon-based active material including a silicon oxide (SiOx, 0<x<2). A content of the first silicon-based active material is in a range from 2 wt % to 40 wt % based on a total weight of the anode active material layer.

Abstract: The present disclosure relates to a fructose-C4-epimerase and a method of preparing tagatose using the same.

Abstract: A polarizing plate and an optical display apparatus are disclosed. A polarizing plate includes a polarizer and a stack of retardation layers on a surface of the polarizer, and the stack of retardation layers includes a second retardation layer and a first retardation layer stacked on the polarizer in sequence from the surface of the polarizer, the second retardation layer being a non-liquid crystal layer, and the stack of retardation layers has an out-of-plane retardation of ?40 nm or more to less than 0 nm at a wavelength of 550 nm and satisfies Relation 1.

Abstract: A display device includes a display panel including a display layer having light-emitting elements on the substrate, and a sensor electrode layer on the display layer. The sensor electrode layer includes sensor electrodes in a sensor area, sensor lines electrically connected to the sensor electrodes and a first conductive pattern spaced apart from the sensor lines and sensor electrodes. The sensor lines and the first conductive pattern are in a sensor peripheral area adjacent to the sensor area. The first conductive pattern is an antenna.

Abstract: The semiconductor device include a horizontal layer spaced apart from a lower structure to extend along a direction parallel to the lower structure; a first conductive line extending along a direction perpendicular to the lower structure and coupled to one end of the horizontal layer; a data storage element coupled to the other end of the horizontal layer; and a second conductive line extending along a direction across the horizontal layer, wherein the second conductive line comprises: a high work function electrode; and a low work function electrode having a cup shape laterally oriented and disposed adjacent to the first conductive line and having a lower work function than the high work function electrode.

Abstract: A lithium secondary battery is disclosed. In some implementations, the lithium secondary battery includes a positive electrode including a positive electrode active material including lithium metal oxide including nickel (Ni) and a negative electrode including a negative electrode active material including a silicon-based active material, wherein the positive electrode active material includes 10 wt % or more of lithium metal oxide in the form of single particles based on a total weight of the positive electrode active material, and the negative electrode active material includes 1 to 15 wt % of the silicon-based active material based on a total weight of the negative electrode active material.

Abstract: A light-emitting diode (LED) lamp for a vehicle and a method of manufacturing the same use MID and magnetic induction technologies. The LED lamp includes a LED module, a housing accommodating the LED module, and a molded interconnect device (MID) electrode formed on a surface of the housing. The LED module may be mounted on the MID electrode by soldering using magnetic induction heating, the housing may be an injection molded product, and the MID electrode may be formed on the housing using a MID process.

Abstract: An anode for a secondary battery includes an anode current collector, a first anode mixture layer on at least one surface of the anode current collector, and a second anode mixture layer on the first anode mixture layer. The first anode mixture layer includes a first silicon-based active material having a carbon coating layer formed on a surface, and a first conductive material, the second anode mixture layer includes a second silicon-based active material doped with a metal, and a second conductive material, and the anode for a secondary battery exhibits a Radial Breathing Mode (RBM) peak in a Raman spectrum obtained from a surface of the second anode mixture layer. An influence of volume expansion/contraction of a silicon-based active material during battery charging/discharging may be alleviated.

Abstract: The present invention relates to a novel antibody specifically binding to OX40L and a bispecific antibody specifically binding to OX40L and TNF? and, specifically, to an antibody or a bispecific antibody specifically binding to human OX40L to effectively inhibit the binding of OX40 to an OX40 receptor; a nucleic acid encoding the antibody; an expression vector comprising the nucleic acid; a transformant comprising the expression vector; a method for preparing the antibody; a pharmaceutical composition for treating autoimmune diseases or inflammatory diseases, comprising the antibody; a composition for diagnosing autoimmune diseases or inflammatory diseases, comprising the antibody; a method for diagnosing autoimmune diseases or inflammatory diseases by using the antibody; a method for providing information on diagnosis of autoimmune diseases or inflammatory diseases by using the antibody; and a kit for providing the same.

Abstract: An anode for a secondary battery is disclosed. In some implementations, the anode includes an anode current collector, a first anode mixture layer on at least one surface of the anode current collector, and a second anode mixture layer on the first anode mixture layer. The first anode mixture layer includes a first silicon-based active material including a carbon coating layer formed on a surface thereof, and a first conductive material. The second anode mixture layer includes a second silicon-based active material doped with a metal, and a second conductive material. The first conductive material has a Raman R value, greater than or equal to a Raman R value of the second conductive material. According to some implementations, volume expansion/contraction of a silicon-based active material may be alleviated during battery charging/discharging.

Abstract: The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound according to the present disclosure as an organic electroluminescent material, an organic electroluminescent device having long lifespan characteristics can be provided.

Abstract: A pharmaceutical composition containing a compound of Formula 1 or Formula 2 below or a pharmaceutically acceptable salt thereof. The composition is suitable for preventing or treating RON-mutation-associated biliary tract cancer. The pharmaceutical composition can be applied to a biliary tract cancer patient having a RON mutation. Particularly, the pharmaceutical composition can be effectively used for treating a biliary tract cancer patient who is resistant to cetuximab, which is conventionally used for cancer treatment, and who has mutation at RONA 155, RON?160 or RON?165.

Abstract: A glass article has a thickness in a range of 20 ?m to 100 ?m and a third elastic energy index of 1.8 MPa2/m0.5 or greater, where the third elastic energy index is defined by Equation 2-3: Third elastic energy index (Eelas3)=GIC×(1/B)×Eabs (Equation 2-3), where GIC is a fracture energy index defined by Equation 1: Fracture energy index (GIC)=(KIC2×(1?v2))/E (Equation 1), where KIC is fracture toughness, v is Poisson's ratio, and E is Young's modulus, B is brittleness (fracture toughness KIC/hardness Hv), and Eabs is absorption energy defined by Equation A: Absorption energy (Eabs)=?2×(1?v)/E (Equation A), where ? is surface strength defined by Equation B: Surface strength (?)=(E×?×?2)/(1?v) (Equation B), where E is Young's modulus, ? is a thermal expansion coefficient, ? is density, and v is Poisson's ratio.

Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.

Abstract: The present invention relates to a biomarker for predicting susceptibility to an MET inhibitor, and a use thereof, and more specifically, the present invention provides a method for predicting susceptibility to the MET inhibitor. According to the present invention, the present invention has an excellent effect of predicting susceptibility to the MET inhibitor for stomach cancer or lung cancer, and thus the present invention may be usefully employed for treating stomach cancer or lung cancer.

Abstract: The present disclosure relates to a new biomarker for predicting susceptibility to an EGFR-targeted agent and a use thereof, and more particularly, provides a biomarker for predicting susceptibility to an EGFR (Epidermal Growth Factor Receptor)-targeted agent, comprising a RON (Recepteur d' Origine Nantais) gene; a composition for predicting susceptibility to the EGFR-targeted agent, comprising an agent which measures a gene expression level of the biomarker; or an expression or activity level of a protein thereof; a composition for enhancing the susceptibility to the EGFR-targeted agent, comprising an inhibitor of the expression of the gene or the expression or activity of the protein of the gene as active ingredients; a kit for predicting the susceptibility to the EGFR-targeted agent, comprising the composition; and a method for predicting the susceptibility to the EGFR-targeted agent.

Abstract: The present disclosure relates to a new biomarker for predicting susceptibility to an EGFR-targeted agent and a use thereof, and more particularly, provides a biomarker for predicting susceptibility to an EGFR (Epidermal Growth Factor Receptor)-targeted agent, comprising a RON (Recepteur d' Origine Nantais) gene; a composition for predicting susceptibility to the EGFR-targeted agent, comprising an agent which measures a gene expression level of the biomarker; or an expression or activity level of a protein thereof; a composition for enhancing the susceptibility to the EGFR-targeted agent, comprising an inhibitor of the expression of the gene or the expression or activity of the protein of the gene as active ingredients; a kit for predicting the susceptibility to the EGFR-targeted agent, comprising the composition; and a method for predicting the susceptibility to the EGFR-targeted agent.